Driving Innovation

HAV logo

Licensing and Investment

Suitably qualified investors who wish to invest in HVL should contact our Corporate Director, Michael Stallibrass, at stalli@hav-vaccines.com

HVL will only consider investments of £50,000 or more

HVL plans to license the animal health rights and, separately, the human health rights to appropriate international healthcare companies who can complete the clinical development and commercialise the vaccines on a major regional or global basis. Interested parties should contact Michael Stallibrass, at stalli@hav-vaccines.com

For further information about the vaccine and its development, please contact our Chief Scientific and Medical Officer, Prof John Hermon-Taylor, at john@hav-vaccines.com